OBJECTIVE: Familial hemophagocytic lymphohistiocytosis (FHLH) is a complex cytokine storm syndrome caused by genetic abnormalities rendering CD8+ T cells and natural killer cells incapable of cytolytic killing. In murine models of FHLH, interferon-γ (IFNγ) produced by CD8+ T cells has been identified as a critical mediator of disease, and an IFNγ-blocking antibody (emapalumab) has recently been approved by the Food and Drug Administration. However, development of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in patients who are genetically unresponsive to IFNγ questions the absolute necessity of IFNγ in driving disease. This study was undertaken to determine the necessity of IFNγ in driving HLH. METHODS: IFNγ-/- Prf1-/- mice were infected with lymphocytic choriomeningitis virus (LCMV), and HLH immunopathologic features, including survival, weight loss, cytopenias, cytokine profiles, and immune cell phenotypes, were assessed. Mixed bone marrow chimeras were created to determine the immune cell-intrinsic role of IFNγ receptor signaling. CD8+ T cell depletion and interleukin-33 (IL-33)/ST2 blockade were performed using monoclonal antibodies. RESULTS: LCMV infection of IFNγ-/- Prf1-/- mice resulted in severe HLH-like disease. CD8+ T cells and the IL-33/ST2 axis remained essential mediators of disease; however, IFNγ-independent HLH immunopathology correlated with a 10-15-fold increase in neutrophilia (P < 0.001) and an altered cytokine milieu dominated by IL-6, IL-1β, and granulocyte-macrophage colony-stimulating factor (GM-CSF) (P < 0.05). Furthermore, IFNγ regulated CD8+ T cell expression of GM-CSF and neutrophil survival. CONCLUSION: IFNγ is not necessary for the development of fulminant HLH, requiring physicians to consider case-by-case treatment strategies. Use of therapies that target upstream activators of CD8+ T cells, such as IL-33/ST2 signaling, may be more universally applicable treatment options that ameliorate both IFNγ-dependent and -independent manifestations of HLH/MAS.
OBJECTIVE:Familial hemophagocytic lymphohistiocytosis (FHLH) is a complex cytokine storm syndrome caused by genetic abnormalities rendering CD8+ T cells and natural killer cells incapable of cytolytic killing. In murine models of FHLH, interferon-γ (IFNγ) produced by CD8+ T cells has been identified as a critical mediator of disease, and an IFNγ-blocking antibody (emapalumab) has recently been approved by the Food and Drug Administration. However, development of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in patients who are genetically unresponsive to IFNγ questions the absolute necessity of IFNγ in driving disease. This study was undertaken to determine the necessity of IFNγ in driving HLH. METHODS: IFNγ-/- Prf1-/- mice were infected with lymphocytic choriomeningitis virus (LCMV), and HLH immunopathologic features, including survival, weight loss, cytopenias, cytokine profiles, and immune cell phenotypes, were assessed. Mixed bone marrow chimeras were created to determine the immune cell-intrinsic role of IFNγ receptor signaling. CD8+ T cell depletion and interleukin-33 (IL-33)/ST2 blockade were performed using monoclonal antibodies. RESULTS:LCMV infection of IFNγ-/- Prf1-/- mice resulted in severe HLH-like disease. CD8+ T cells and the IL-33/ST2 axis remained essential mediators of disease; however, IFNγ-independent HLH immunopathology correlated with a 10-15-fold increase in neutrophilia (P < 0.001) and an altered cytokine milieu dominated by IL-6, IL-1β, and granulocyte-macrophage colony-stimulating factor (GM-CSF) (P < 0.05). Furthermore, IFNγ regulated CD8+ T cell expression of GM-CSF and neutrophil survival. CONCLUSION: IFNγ is not necessary for the development of fulminant HLH, requiring physicians to consider case-by-case treatment strategies. Use of therapies that target upstream activators of CD8+ T cells, such as IL-33/ST2 signaling, may be more universally applicable treatment options that ameliorate both IFNγ-dependent and -independent manifestations of HLH/MAS.
Authors: E Brisse; M Imbrechts; T Mitera; J Vandenhaute; N Berghmans; L Boon; C Wouters; R Snoeck; G Andrei; P Matthys Journal: Clin Exp Immunol Date: 2018-01-18 Impact factor: 4.330
Authors: Unni Krishna S R L Samavedam; Hiroaki Iwata; Susen Müller; Franziska S Schulze; Andreas Recke; Enno Schmidt; Detlef Zillikens; Ralf J Ludwig Journal: J Immunol Date: 2013-12-11 Impact factor: 5.422
Authors: Janos Sumegi; Michael G Barnes; Shawnagay V Nestheide; Susan Molleran-Lee; Joyce Villanueva; Kejian Zhang; Kimberly A Risma; Alexei A Grom; Alexandra H Filipovich Journal: Blood Date: 2011-02-16 Impact factor: 22.113
Authors: Serani L H van Dommelen; Nital Sumaria; Robert D Schreiber; Anthony A Scalzo; Mark J Smyth; Mariapia A Degli-Esposti Journal: Immunity Date: 2006-11 Impact factor: 31.745
Authors: Hamza O Yazdani; Hui-Wei Chen; Samer Tohme; Sheng Tai; Dirk J van der Windt; Patricia Loughran; Brian R Rosborough; Vikas Sud; Donna Beer-Stolz; Heth R Turnquist; Allan Tsung; Hai Huang Journal: J Hepatol Date: 2017-09-21 Impact factor: 25.083
Authors: Misty R Jenkins; Jesse A Rudd-Schmidt; Jamie A Lopez; Kelly M Ramsbottom; Stuart I Mannering; Daniel M Andrews; Ilia Voskoboinik; Joseph A Trapani Journal: J Exp Med Date: 2015-03-02 Impact factor: 14.307
Authors: Paul Tsoukas; Emily Rapp; Lauren Van Der Kraak; Eric S Weiss; Vinh Dang; Corinne Schneider; Edwin Klein; Jennifer Picarsic; Rosalba Salcedo; C Andrew Stewart; Scott W Canna Journal: Blood Date: 2020-11-05 Impact factor: 22.113
Authors: Tamir Diamond; Thomas N Burn; Mailyn A Nishiguchi; Danielle Minichino; Julie Chase; Niansheng Chu; Portia A Kreiger; Edward M Behrens Journal: PLoS One Date: 2022-06-07 Impact factor: 3.752
Authors: Puja Mehta; Joanna C Porter; Jessica J Manson; John D Isaacs; Peter J M Openshaw; Iain B McInnes; Charlotte Summers; Rachel C Chambers Journal: Lancet Respir Med Date: 2020-06-16 Impact factor: 30.700
Authors: Giacomo De Luca; Giulio Cavalli; Corrado Campochiaro; Emanuel Della-Torre; Piera Angelillo; Alessandro Tomelleri; Nicola Boffini; Stefano Tentori; Francesca Mette; Nicola Farina; Patrizia Rovere-Querini; Annalisa Ruggeri; Teresa D'Aliberti; Paolo Scarpellini; Giovanni Landoni; Francesco De Cobelli; John F Paolini; Alberto Zangrillo; Moreno Tresoldi; Bruce C Trapnell; Fabio Ciceri; Lorenzo Dagna Journal: Lancet Rheumatol Date: 2020-06-16